Of note, this role is appreciable only in oncogene-driven genetic backgrounds (i.e., KRAS-mutated cells), thus suggesting that LKB1 loss might occur as a secondary oncogenic lesion that facilitates tumor progression in cells with one constitutively active oncogene. The gene discussed is KRAS; the disease is neoplasm.